Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer

AI Insight

This study evaluated the combination of anbenitamab (a HER2-targeting antibody-drug conjugate) plus HB1801 (an oral tyrosine kinase inhibitor) in patients with HER2-positive advanced breast cancer. The treatment regimen showed promising antitumor activity in this patient population, which had previously received multiple lines of HER2-directed therapy. The trial assessed the safety profile and efficacy outcomes of this novel drug combination.

Why it matters

HER2-positive breast cancer affects approximately 15-20% of breast cancer patients, and new treatment options are needed for those whose disease has progressed on standard therapies. This combination therapy represents a potential new treatment approach for patients with limited options after exhausting conventional HER2-targeted treatments.